Compare HFFG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | ABOS |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.8M | 197.9M |
| IPO Year | 2016 | 2021 |
| Metric | HFFG | ABOS |
|---|---|---|
| Price | $1.68 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | 100.9K | ★ 358.2K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $1,228,282,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $24.43 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $1.21 |
| 52 Week High | $3.59 | $3.60 |
| Indicator | HFFG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 49.79 |
| Support Level | $1.40 | $2.76 |
| Resistance Level | $1.97 | $3.02 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 13.11 | 16.39 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.